Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973341 | 0.92 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11NR1I2 | |
| SCHEMBL3975446 | 0.87 | LMNA (0.41) | MAPK14MAPK13MAPK12MAPK11NR1I2 | |
| SCHEMBL3974075 | 0.87 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL3971185 | 0.83 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11ACLY | |
| SCHEMBL3974419 | 0.81 | LMNA (0.39) | POLBTDP1GFERACLY | |
| SCHEMBL3883353 | 0.80 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11ACLY | |
| SCHEMBL3980188 | 0.80 | MAPK13 (0.43) | MAPK14MAPK13MAPK12MAPK11ACLY | |
| SCHEMBL3977790 | 0.80 | MAPK13 (0.42) | MAPK14MAPK13MAPK12MAPK11ACLY | |
| SCHEMBL3972865 | 0.79 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3975282 | 0.79 | MAPK14 (0.42) | MAPK14MAPK13MAPK12MAPK11ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | MAPK14 2768/4885MAPK13 1918/4885MAPK12 2241/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | MAPK14 2768/4885MAPK13 1918/4885MAPK12 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.